China · Delayed Price · Currency is CNY Bide Pharmatech Statistics
Total Valuation
Bide Pharmatech has a market cap or net worth of CNY 5.15 billion. The enterprise value is 4.25 billion.
| Market Cap | 5.15B |
| Enterprise Value | 4.25B |
Important Dates
The last earnings date was Thursday, April 23, 2026.
| Earnings Date | Apr 23, 2026 |
| Ex-Dividend Date | Jun 9, 2025 |
Share Statistics
Bide Pharmatech has 86.15 million shares outstanding. The number of shares has decreased by -1.40% in one year.
| Current Share Class | 86.15M |
| Shares Outstanding | 86.15M |
| Shares Change (YoY) | -1.40% |
| Shares Change (QoQ) | +1.41% |
| Owned by Insiders (%) | 51.45% |
| Owned by Institutions (%) | 19.89% |
| Float | 30.57M |
Valuation Ratios
The trailing PE ratio is 34.53 and the forward PE ratio is 25.26.
| PE Ratio | 34.53 |
| Forward PE | 25.26 |
| PS Ratio | 3.89 |
| PB Ratio | 2.52 |
| P/TBV Ratio | 2.53 |
| P/FCF Ratio | 1,273.64 |
| P/OCF Ratio | 181.68 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.36, with an EV/FCF ratio of 1,050.78.
| EV / Earnings | 27.98 |
| EV / Sales | 3.21 |
| EV / EBITDA | 16.36 |
| EV / EBIT | 17.57 |
| EV / FCF | 1,050.78 |
Financial Position
The company has a current ratio of 6.74, with a Debt / Equity ratio of 0.07.
| Current Ratio | 6.74 |
| Quick Ratio | 3.86 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.54 |
| Debt / FCF | 34.92 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 7.45% and return on invested capital (ROIC) is 16.80%.
| Return on Equity (ROE) | 7.45% |
| Return on Assets (ROA) | 6.12% |
| Return on Invested Capital (ROIC) | 16.80% |
| Return on Capital Employed (ROCE) | 11.11% |
| Weighted Average Cost of Capital (WACC) | 7.47% |
| Revenue Per Employee | 1.79M |
| Profits Per Employee | 205,609 |
| Employee Count | 129 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 0.85 |
Taxes
In the past 12 months, Bide Pharmatech has paid 43.69 million in taxes.
| Income Tax | 43.69M |
| Effective Tax Rate | 22.36% |
Stock Price Statistics
The stock price has increased by +39.91% in the last 52 weeks. The beta is 0.62, so Bide Pharmatech's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +39.91% |
| 50-Day Moving Average | 57.69 |
| 200-Day Moving Average | 64.57 |
| Relative Strength Index (RSI) | 48.60 |
| Average Volume (20 Days) | 1,566,220 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bide Pharmatech had revenue of CNY 1.32 billion and earned 151.74 million in profits. Earnings per share was 1.73.
| Revenue | 1.32B |
| Gross Profit | 589.57M |
| Operating Income | 241.65M |
| Pretax Income | 195.43M |
| Net Income | 151.74M |
| EBITDA | 256.13M |
| EBIT | 241.65M |
| Earnings Per Share (EPS) | 1.73 |
Balance Sheet
The company has 1.04 billion in cash and 141.07 million in debt, with a net cash position of 900.41 million or 10.45 per share.
| Cash & Cash Equivalents | 1.04B |
| Total Debt | 141.07M |
| Net Cash | 900.41M |
| Net Cash Per Share | 10.45 |
| Equity (Book Value) | 2.05B |
| Book Value Per Share | 24.17 |
| Working Capital | 1.96B |
Cash Flow
In the last 12 months, operating cash flow was 28.32 million and capital expenditures -24.28 million, giving a free cash flow of 4.04 million.
| Operating Cash Flow | 28.32M |
| Capital Expenditures | -24.28M |
| Depreciation & Amortization | 14.48M |
| Net Borrowing | 56.43M |
| Free Cash Flow | 4.04M |
| FCF Per Share | 0.05 |
Margins
Gross margin is 44.54%, with operating and profit margins of 18.25% and 11.46%.
| Gross Margin | 44.54% |
| Operating Margin | 18.25% |
| Pretax Margin | 14.76% |
| Profit Margin | 11.46% |
| EBITDA Margin | 19.35% |
| EBIT Margin | 18.25% |
| FCF Margin | 0.31% |
Dividends & Yields
This stock pays an annual dividend of 0.90, which amounts to a dividend yield of 1.55%.
| Dividend Per Share | 0.90 |
| Dividend Yield | 1.55% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 52.02% |
| Buyback Yield | 1.40% |
| Shareholder Yield | 3.02% |
| Earnings Yield | 2.95% |
| FCF Yield | 0.08% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 25, 2023. It was a forward split with a ratio of 1.4.
| Last Split Date | May 25, 2023 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |